166 related articles for article (PubMed ID: 35986757)
1. FLOT and CROSS chemotherapy regimens alter the frequency of CD27
Davern M; Donlon NE; Sheppard AS; Majcher KD; Connell FO; Heeran AB; Grant M; Farrell RA; Hayes C; Bracken-Clarke D; Conroy MJ; Foley E; Toole DO; Bhardwaj A; Ravi N; Reynolds JV; Maher SG; Sullivan JO; Lysaght J
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3753-3774. PubMed ID: 35986757
[TBL] [Abstract][Full Text] [Related]
2. Cooperation between chemotherapy and immune checkpoint blockade to enhance anti-tumour T cell immunity in oesophageal adenocarcinoma.
Davern M; Donlon NE; O' Connell F; Sheppard AD; Hayes C; King R; Temperley H; Butler C; Bhardwaj A; Moore J; Bracken-Clarke D; Donohoe C; Ravi N; Reynolds JV; Maher SG; Conroy MJ; Lysaght J
Transl Oncol; 2022 Jun; 20():101406. PubMed ID: 35366537
[TBL] [Abstract][Full Text] [Related]
3. Visceral adipose tissue secretome from early and late-stage oesophageal cancer patients differentially affects effector and regulatory T cells.
Davern M; Bracken-Clarke D; Donlon NE; Sheppard AD; Connell FO; Heeran AB; Majcher K; Conroy MJ; Mylod E; Butler C; Donohoe C; Donnell DO; Lowery M; Bhardwaj A; Ravi N; Melo AA; Sullivan JO; Reynolds JV; Lysaght J
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6583-6599. PubMed ID: 36790524
[TBL] [Abstract][Full Text] [Related]
4. Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy.
Davern M; Donlon NE; O'Connell F; Gaughan C; O'Donovan C; McGrath J; Sheppard AD; Hayes C; King R; Temperley H; MacLean M; Bulter C; Bhardwaj A; Moore J; Donohoe C; Ravi N; Conroy MJ; Reynolds JV; Lysaght J
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5377-5395. PubMed ID: 36445478
[TBL] [Abstract][Full Text] [Related]
5. Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma - A comparison of the FLOT and 'MAGIC' regimens.
Moore JL; Kumar S; Santaolalla A; Patel PH; Kapiris M; Van Hemelrijck M; Maisey N; Hill M; Lagergren J; Gossage JA; Kelly M; Chaudry A; Allum WH; Baker CR; Cunningham D; Davies AR;
Eur J Cancer; 2022 Mar; 163():180-188. PubMed ID: 35085931
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy regimens induce inhibitory immune checkpoint protein expression on stem-like and senescent-like oesophageal adenocarcinoma cells.
Davern M; Donlon NE; Sheppard A; Connell FO; Hayes C; Bhardwaj A; Foley E; Toole DO; Lynam-Lennon N; Ravi N; Reynolds JV; Maher SG; Lysaght J
Transl Oncol; 2021 Jun; 14(6):101062. PubMed ID: 33765543
[TBL] [Abstract][Full Text] [Related]
7. Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
Dos Santos M; Lequesne J; Leconte A; Corbinais S; Parzy A; Guilloit JM; Varatharajah S; Brachet PE; Dorbeau M; Vaur D; Weiswald LB; Poulain L; Le Gallic C; Castera-Tellier M; Galais MP; Clarisse B
BMC Cancer; 2022 May; 22(1):537. PubMed ID: 35549674
[TBL] [Abstract][Full Text] [Related]
8. PD-1 blockade attenuates surgery-mediated immunosuppression and boosts Th1 immunity perioperatively in oesophagogastric junctional adenocarcinoma.
Davern M; Gaughan C; O' Connell F; Moran B; Mylod E; Sheppard AD; Ramjit S; Yun-Tong Kung J; Phelan JJ; Davey MG; Ryan EJ; Butler C; Quinn L; Howard C; Tone E; Phoenix E; Butt WT; Lynam-Lennon N; Maher SG; Ravi N; Donohoe CL; Reynolds JV; Lysaght J; Donlon NE
Front Immunol; 2023; 14():1150754. PubMed ID: 37359545
[TBL] [Abstract][Full Text] [Related]
9. PD-1 blockade enhances chemotherapy toxicity in oesophageal adenocarcinoma.
Davern M; O' Brien RM; McGrath J; Donlon NE; Melo AM; Buckley CE; Sheppard AD; Reynolds JV; Lynam-Lennon N; Maher SG; Lysaght J
Sci Rep; 2022 Feb; 12(1):3259. PubMed ID: 35228614
[TBL] [Abstract][Full Text] [Related]
10. Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study.
Moussa O; Bhogal RH; Malietzis G; Fribbens C; Starling N; Gerlinger M; Watkins D; Chau I; Rao S; Cunningham D; Allum WH; Chaudry A; Kumar S
BJS Open; 2022 Jan; 6(1):. PubMed ID: 35195263
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of tumor regression by neoadjuvant chemotherapy regimens for esophageal adenocarcinoma: a systematic review and meta-analysis.
Chidambaram S; Sounderajah V; Maynard N; Owen R; Markar SR
Dis Esophagus; 2023 Jan; 36(2):. PubMed ID: 36151055
[TBL] [Abstract][Full Text] [Related]
12. Site distribution of oesophagogastric cancer.
Byrne JP; Mathers JM; Parry JM; Attwood SE; Bancewicz J; Woodman CB
J Clin Pathol; 2002 Mar; 55(3):191-4. PubMed ID: 11896070
[TBL] [Abstract][Full Text] [Related]
13. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
[TBL] [Abstract][Full Text] [Related]
14. The genomic landscape of oesophagogastric junctional adenocarcinoma.
Chong IY; Cunningham D; Barber LJ; Campbell J; Chen L; Kozarewa I; Fenwick K; Assiotis I; Guettler S; Garcia-Murillas I; Awan S; Lambros M; Starling N; Wotherspoon A; Stamp G; Gonzalez-de-Castro D; Benson M; Chau I; Hulkki S; Nohadani M; Eltahir Z; Lemnrau A; Orr N; Rao S; Lord CJ; Ashworth A
J Pathol; 2013 Nov; 231(3):301-10. PubMed ID: 24308032
[TBL] [Abstract][Full Text] [Related]
15. Recent trends and predictors of multimodality treatment for oesophageal, oesophagogastric junction, and gastric cancer: A Dutch cohort-study.
Trip AK; Stiekema J; Visser O; Dikken JL; Cats A; Boot H; van Sandick JW; Jansen EP; Verheij M
Acta Oncol; 2015 Nov; 54(10):1754-62. PubMed ID: 25797568
[TBL] [Abstract][Full Text] [Related]
16. Real-World Outcomes of FLOT versus CROSS Regimens for Patients with Oesophagogastric Cancers.
Shahnam A; Nindra U; McNamee N; Yoon R; Asghari R; Ng W; Karikios D; Wong M
Gastrointest Tumors; 2023; 10(1):19-28. PubMed ID: 37901653
[TBL] [Abstract][Full Text] [Related]
17. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.
Zhou G; Sprengers D; Mancham S; Erkens R; Boor PPC; van Beek AA; Doukas M; Noordam L; Campos Carrascosa L; de Ruiter V; van Leeuwen RWF; Polak WG; de Jonge J; Groot Koerkamp B; van Rosmalen B; van Gulik TM; Verheij J; IJzermans JNM; Bruno MJ; Kwekkeboom J
J Hepatol; 2019 Oct; 71(4):753-762. PubMed ID: 31195061
[TBL] [Abstract][Full Text] [Related]
18. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.
Lorenzen S; Biederstädt A; Ronellenfitsch U; Reißfelder C; Mönig S; Wenz F; Pauligk C; Walker M; Al-Batran SE; Haller B; Hofheinz RD
BMC Cancer; 2020 Sep; 20(1):886. PubMed ID: 32933498
[TBL] [Abstract][Full Text] [Related]
19. Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
Tomita Y; Moldovan M; Chang Lee R; Hsieh AH; Townsend A; Price T
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD012078. PubMed ID: 33210731
[TBL] [Abstract][Full Text] [Related]
20. Complete Remission of Metastatic HER2+ Oesophagogastric Junctional Adenocarcinoma under long-term Trastuzumab Treatment.
Gutting T; Schulte N; Belle S; Betge J; Härtel N; Wilke J; Weers J; Ebert MP; Zhan T
J Gastrointestin Liver Dis; 2019 Dec; 28(4):503-507. PubMed ID: 31826054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]